利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.041 秒)

    BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
    10.
    发明申请
    BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER 审中-公开
    用于BEVACIZUMAB联合治疗乳腺癌的血浆等离子体生物标志物

    公开(公告)号：US20140341893A1

    公开(公告)日：2014-11-20

    申请号：US14289524

    申请日：2014-05-28

    申请人： Genentech, Inc.

    发明人： Herbert Andres ,  Sanne Lysbet de Haas ,  Rebecca Elliott ,  Johann Karl ,  Yu-Ju Gloria Meng ,  Gregory D. Plowman ,  Stefan Scherer ,  Norbert Wild

    IPC分类号： A61K39/395 ,  C07K16/22 ,  G01N33/574 ,  A61K31/337

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  C07K16/22 ,  G01N33/57415 ,  G01N2333/475

    摘要： The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

    摘要翻译： 本发明提供了通过将化疗方案添加到化疗方案中来改善患有HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的化疗方案的治疗效果的方法， 相对于诊断为HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的对照水平，VEGFA和/或VEGFR2的水平，特别是血浆表达水平。 本发明还提供了通过确定VEGFA和/或VEGFR2相对的表达水平，特别是血浆表达水平来评估患者与贝伐珠单抗（Avastin？）联合化疗方案的敏感性或反应性的方法 以控制诊断为HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌患者的水平。